Eyelid Malignancy: Basics

The eyelid contains multiple tissue layers and glandular structures (skin, orbicularis muscle, tarsus with meibomian glands, and conjunctiva), each of which can give rise to a distinct malignancy. Eyelid malignancies encompass five major tumor types — basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, melanoma, and Merkel cell carcinoma — representing a significant health burden, particularly in high-UV-exposure regions.¹

Each malignancy arises from a distinct cell of origin with distinct behavior: basal cell carcinoma (basal keratinocytes, locally invasive, rarely metastasizes), squamous cell carcinoma (keratinocytes, higher metastatic risk especially if immunosuppressed), sebaceous gland carcinoma (sebaceous glands, notorious for masquerading as benign inflammatory conditions with pagetoid spread), melanoma (melanocytes, highest metastatic potential), and Merkel cell carcinoma (neuroendocrine cells, rare but highly aggressive).

Shared warning signs include a non-healing lesion, madarosis, ulceration, induration, telangiectatic vessels, and lesions mimicking but not responding to treatment for a benign condition. Basal cell carcinoma classically presents as a pearly, telangiectatic nodule. Sebaceous gland carcinoma can present as a recurrent "chalazion" or chronic unilateral blepharitis.

Key differentials: chalazion/hordeolum (must exclude via biopsy in atypical/recurrent cases), chronic blepharitis, benign nevus (vs. melanoma), and actinic keratosis (vs. SCC).

Diagnosis of a suspicious lesion requires biopsy, since clinical appearance alone is often insufficient, particularly for sebaceous gland carcinoma. In a 17-year retrospective analysis, basal cell carcinoma was the most common tumor type (52.6%), followed by sebaceous cell carcinoma (32.2%).² Regional lymph node assessment is important for higher-risk tumor types.

Microscopically controlled surgical excision is the mainstay of curative therapy, with margins tailored to tumor type; Mohs micrographic surgery improves local control and tissue preservation.¹ In the 17-year analysis, direct lid closure was the most frequent reconstructive method, postoperative complications (ectropion, entropion, canalicular obstruction) were minimal, and recurrence occurred in 13 of 152 patients; lymph node involvement and positive intraoperative frozen margins were the strongest predictors of local recurrence.² For unresectable/metastatic disease, checkpoint inhibitors (PD-1/PD-L1) and hedgehog pathway inhibitors have shown enhanced progression-free survival and durable responses in melanoma, Merkel cell carcinoma, and advanced SCC.¹ Management is increasingly multidisciplinary.¹

• Basal cell carcinoma is the most common eyelid malignancy, followed by sebaceous cell carcinoma²
• Any atypical/recurrent "chalazion" or unilateral chronic blepharitis warrants biopsy to exclude sebaceous gland carcinoma
• Microscopically controlled excision (Mohs) balances complete removal against tissue preservation¹
• Lymph node involvement and positive frozen margins are the strongest recurrence predictors²
• Immunotherapy/targeted agents have expanded options for unresectable/metastatic disease¹
• Common pitfall: repeatedly treating a recurrent "chalazion" without ever biopsying it